Primary Outcomes in Psychedelic Trials: Why One Positive Measure Is Not the Whole Result

Many outcomes create many possible stories

A mental health trial may measure symptoms, quality of life, functioning, anxiety, sleep and biological signals. These outcomes are related but can move differently. If readers see only the most favorable measure, they may receive a distorted account of the study. Prespecifying a primary outcome helps define the question the trial was designed to answer.

That commitment is not a bureaucratic detail. Searching many measures and time points increases the chance of a positive finding even when a treatment has limited or no consistent benefit. A responsible report identifies the main outcome and explains whether the highlighted findings were primary, secondary or exploratory.

For further context, see the guide to reading psychedelic trials.

Define the scale and the time point

A depression scale estimates symptom severity using particular questions and scoring rules. A change at six weeks is a different endpoint from change at one year. Even when both are relevant, they do not support identical claims about durability. The 2023 psilocybin depression trial provides a human randomized example with a defined follow-up rather than evidence of permanent remission.

Readers do not need to memorize every scale abbreviation, but they should know what domain was measured and when. A score can be statistically different while the practical significance remains uncertain. Confidence intervals and the distribution of outcomes provide context that a single average cannot capture.

For further context, see the treatment package and follow-up model.

Response and remission are not synonyms

Response usually means meeting a specified improvement threshold. Remission usually means symptoms fall below a specified severity threshold. The definitions depend on the scale and protocol. A participant can improve substantially without meeting remission criteria, or meet a symptom threshold while still facing functional difficulties.

Neither term establishes that an illness will never recur or that other treatment is unnecessary. Reports should avoid turning a percentage of remitters at one visit into a percentage permanently cured. The distinction is particularly important when an intervention is described as rapid, because speed of initial change does not answer the separate question of sustained recovery.

Use a different disorder to see the issue clearly

In the alcohol-use-disorder trial by Bogenschutz and colleagues, the principal outcome concerned the percentage of heavy-drinking days during follow-up. That is not the same as complete abstinence for every participant. A reduction can be clinically relevant without supporting a claim that the treatment eliminated addiction.

Outcome definitions also determine what readers can compare across studies. Different thresholds, follow-up periods and participant populations can make superficially similar percentages misleading. A headline should preserve the actual outcome rather than substitute a more dramatic one. This rule applies across depression, PTSD and substance-use research.

Longer follow-up is valuable but changes the design question

The twelve-month depression follow-up by Gukasyan and colleagues reported sustained improvements in a small cohort. Its later assessments are informative, but they did not retain a continuing randomized untreated comparator. Outcomes may be influenced by additional care, selective follow-up and other events over time.

It is therefore appropriate to describe observed durability while qualifying causal claims. The follow-up does not become a new large randomized trial simply because it lasts longer. Nor should it be dismissed for failing to answer a question it was not designed to settle. The key is to state which kind of evidence it provides.

A practical editorial test

Before writing a result, complete a sentence containing the population, intervention, comparator, primary outcome and time point. If the sentence cannot be completed from the paper, the headline is not ready. Then describe secondary results with their status clear, especially when many analyses were conducted or adjustments for multiple testing were absent.

For an individual reader, ask what the measured change would mean in daily life and what remains unmeasured. Functioning, adverse effects and treatment burden can alter the value of a symptom gain. The strongest interpretation does not demand that one outcome capture everything; it keeps different outcomes distinct so that a promising result is neither exaggerated nor lost in an indiscriminate list of numbers.

Translate the group result without inventing a patient forecast

When an article reports a response percentage, check the denominator: everyone randomized, everyone treated or only people assessed at that visit. Then ask for the corresponding percentage in the comparator group. A treatment-group percentage alone leaves out how often the same endpoint occurred under the alternative condition. Report the absolute difference where the paper supports it, while retaining uncertainty rather than turning a sample estimate into an individual promise.

For continuous symptom scores, ask what the difference means on the particular scale and whether the investigators justified a threshold for a meaningful change. Do not supply a universal threshold across unrelated instruments. Distribution matters too: a similar average can conceal different patterns of improvement, no change and worsening. If that detail is unavailable, acknowledge the gap. This makes an outcome summary more useful than a list of statistically significant findings without implying that every participant experienced the average benefit.

Keep the endpoint definition attached to every numerical claim. A percentage labeled improvement can mislead if the reader cannot tell whether it represents response, remission or a change on a continuous scale.

Sources

• Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.
• Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial.
• Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.

Editorial disclosure: It is educational information, not individual medical advice. Prepared for October 30, 2026 using established research; it does not assert current regulatory status or latest findings.